Director, Discovery Biology Sweden
Rob completed his PhD at the MRC Laboratory of Molecular Biology understanding
EGFR signalling pathways in Drosophila followed by post-doctoral positions at Stanford
University, USA and Cambridge University. In 2001 he joined Vernalis, a UK-based drug
development company where he was in charge of the Screening group working across
several disease areas including Oncology and Neuroscience.
In 2008 he helped start Horizon Discovery, a translational genomics company that uses
the adeno-associated virus (AAV) and other gene targeting technologies such as
CRISPR, to generate isogenic human cell lines. At Horizon he also established their
Centres of Excellence program to enable academic groups with the gene targeting
technologies which included such groups as the National Institutes of Health, Cambridge
University and Yale University.
In 2013 he joined MedImmune, the global biologics division of AstraZeneca, leading the
High Throughput Screening team based in Cambridge, UK.
Tuesday, February 6
10:30 AM – 12:30 PM